Navigation Links
Baxa Corporation Recognized for Pharmacy Automation Leadership and Business Growth
Date:8/25/2010

ENGLEWOOD, Colo., Aug. 25 /PRNewswire/ -- Baxa Corporation today announced its rank of 3,494 on the Inc. 5000 list of the fastest-growing private businesses in the United States. This year marks the fourth consecutive year that Baxa, a leading provider of medical devices and systems that automate pharmacy operations, has been listed on the prestigious Inc. 5000 list.

(Logo:  http://photos.prnewswire.com/prnh/20100817/INC5000LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100817/INC5000LOGO)

"Our growth is due in large part to our continued focus on developing pharmacy technology and automation devices that provide Directors of the Pharmacy with a high degree of safety, speed and certainty in their IV dose preparation," said Greg Baldwin, Baxa Chairman and CEO.  "This focus has led to our continued market penetration and reputation for quality, which have earned Baxa multiple recent accolades, including our fourth year on the Inc. 5000 list."

In addition to the Inc. 5000 listing, Baxa Corporation's market leadership was recently recognized by Pharmacy Purchasing & Products (PP&P), the premier magazine for health system pharmacists, in its August 2010 "Pharmacy Automation Guide."  The market study surveyed more than 400 health system pharmacy directors, with results that show:

  • Baxa holds a 75% share of compounding robots in use with the IntelliFill® i.v. System.
  • Baxa leads the marketplace with a 68% share of automated compounding devices with the ExactaMix™ Automated Compounders.
  • Baxa holds a 50% share of IV workflow management with the DoseEdge® Pharmacy Workflow Manager, including a 64% share of vendor consideration.

  • These findings are further supported by the more t
    '/>"/>

    SOURCE Baxa Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
    2. CEL-SCI Corporation Releases Letter to Shareholders
    3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
    4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
    5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
    6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
    7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
    8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
    9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
    10. Immunosyn Corporation Releases SF-1019 Study Results
    11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... 24, 2014 Kinex Pharmaceuticals announced today that ... Roswell Park Cancer Institute. KX2-361 (KX02), a ... has shown potent inhibitory activity against a broad panel ... resistant to Temozolomide (T98G), the most widely used chemotherapy ... brain tumor mouse model, KX2-361 consistently clears brain tumors ...
    (Date:12/24/2014)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ), the ... Jennifer Hagerman , Pharm.D., AE-C, senior director of ... the president of the Michigan Pharmacists Association on Jan. ... Feb. 28, 2015, at the MPA Annual Convention and ... in Detroit, Michigan . Hagerman will ...
    (Date:12/24/2014)... 2014 Echo Therapeutics, Inc. (NASDAQ: ... on skin permeation, continuous glucose monitoring and associated ... has been appointed Chief Executive Officer effective ... 20 years of experience in the medical device, ... served as Vice President, Business Development, Otsuka Pharmaceuticals as ...
    Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
    ... showed patients taking prasugrel had lower ... stroke or cardiovascular death after first event than ... A new,pre-specified analysis of the landmark Phase III ... acute coronary syndromes,(ACS) managed with an artery-opening procedure known ...
    ... 21 Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today ... in the United Kingdom has authorized a Phase 1,study ... lead product candidate for the treatment of gout., ... 1 study of,RDEA594, within six months from designation as ...
    Cached Medicine Technology:Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events 2Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events 3Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events 4Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events 5Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial 2Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial 3Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial 4
    (Date:12/26/2014)... India Network Foundation, a non-profit US ... announced today a new version of “ EasySelect ”, ... right plan for their visiting parents. The technology tool ... selection process when choosing an insurance plan by showing ... a few clicks. Many elderly Asian Indian parents often ...
    (Date:12/25/2014)... 26, 2014 This is a professional ... global Sterilizers industry with a focus on the Chinese ... status of the Sterilizers manufacturers and is a valuable ... interested in the industry. This report provides a basic ... manufacturing technology. In this part, the report presents the ...
    (Date:12/25/2014)... “Every three months the trends for evening dresses ... will be one of the hottest styles in the next ... the company releases 26 A-line sweetheart evening dresses, and announces ... , “We are trying our best to help a lady ... Along with affordable prices, we provide discounted delivery costs to ...
    (Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and ... Today, the company announces big discounts on its ... colors. , BambooFlooringChina.com is the world’s leader in bamboo ... valid until Jan. 20, 2015. , The bamboo mats ... a natural thread. All the bamboo strips for the ...
    (Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- The risk of ... holidays, so you need to be extra cautious, an ... we see a significant increase in patients coming in ... the Suffolk County Volunteer Firefighters Burn Center of Stony ... should be full of joy, but if not careful, ...
    Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Don't Let Burns Mar Your Holidays 2
    ... At the 14th annual retrovirus conference in Los Angeles, it ... the United States//. According to Harold Jaffe, a professor of ... no signs of decreasing. ,He also ... fresh infection of HIV cases. Jaffe emphasized on the scientific ...
    ... to a latest study, the ages at which teenagers and ... a significant impact on their delinquent behavior//. The level of ... earlier than their peer group and vice versa. ... of Youth and Adolescence. Stacy Armour the co-author of this ...
    ... Inc. today announced the first patient implant in a ... near the spinal cord will control// chronic chest pain ... is the first person to receive this investigational device, ... approximately 1.3 million Americans who suffer from chronic angina, ...
    ... of Technology researchers have engineered a way to deliver ... as carriers. The breakthrough could lead to low fat ... in fat-containing foods, and could be used to enrich ... ,The team, led by Dr. Yoav ...
    ... be in gold nanoparticles - tiny pieces of gold so ... potential of gold nanoparticles has been hindered by the difficulty ... be injected into a patient. New research at the University ... used to overcome this problem, creating a new type of ...
    ... the world's leading pharmaceutical companies, issued a press release ... metastatic prostate cancer. ,A Phase III ... to Novantrone (mitoxantrone) plus prednisone. The study included a ... spread of disease after hormonal therapy., ,The results ...
    Cached Medicine News:Health News:Spinal Cord Stimulation Pilot Study for Chronic Angina 2Health News:Natural Milk Protein Could Lead to Super Nutritious Foods 2Health News:Common Ingredient in Big Macs and Sodas Can Stabilize Gold Nanoparticles for Medical Use 2Health News:Common Ingredient in Big Macs and Sodas Can Stabilize Gold Nanoparticles for Medical Use 3
    These retractors are packaged singly ready for sterilization at your facility....
    These retractors are packaged singly ready for sterilization at your facility....
    HemoNIR™ is a portable device that measures the ability of apersons blood to carry oxygen by monitoring functional vs. non functional hemoglobin....
    ... aureus and methicillin resistant coagulase-negative staphylococci in ... MRSA Latex Kit for PBP2/ detects Penicillin ... Staphylococcus aureus and coagulase-negative staphylococci. PBP2/ is ... and is present in the membranes of ...
    Medicine Products: